Follow us on Twitter
twitter icon@FreshPatents


Immunogenic patents

      

This page is updated frequently with new Immunogenic-related patent applications.




 Anti-b7-h3 antibodies and diagnostic uses thereof patent thumbnailAnti-b7-h3 antibodies and diagnostic uses thereof
Provided herein are b7-h3 antibodies, fragments of such antibodies, and compositions comprising the same. The antibodies, antibody fragments and compositions are useful in a number of analytical methods, including immunohistochemical and immunocytochemical detection and analysis of b7-h3.
Spring Bioscience Corporation


 Monoclonal antibodies to interleukin 35 and methods of use thereof to inhibit regulatory t cell function patent thumbnailMonoclonal antibodies to interleukin 35 and methods of use thereof to inhibit regulatory t cell function
Methods for regulating t cell function in a subject, particularly regulatory t cell activity are provided. Methods of the invention include administering to a subject a therapeutically effective amount of an interleukin 35-specific binding agent, such as an antibody or small molecule inhibitor.
St. Jude Children's Research Hospital


 Mrka polypeptides, antibodies, and uses thereof patent thumbnailMrka polypeptides, antibodies, and uses thereof
The present disclosure provides mrka binding proteins, e.g., antibodies or antigen binding fragments thereof that bind to mrka and induce opsonophagocytic killing of klebsiella (e.g., klebsiella pneumoniae). The present disclosure also provides methods of reducing klebsiella (e.g., klebsiella pneumoniae) or treating or preventing klebsiella (e.g., klebsiella pneumoniae) infection in a subject comprising administering mrka binding proteins, e.g., antibodies or antigen-binding fragments thereof, mrka polypeptides, immunogenic fragments thereof, or polynucleotides encoding mrka or immunogenic fragments thereof to the subject..
Medimmune, Llc


 Novel immunogenic composition patent thumbnailNovel immunogenic composition
Recombinant chimeric viruses based on ndv lasota strain and containing either iltv gb or gd are produced. Administration of the chimeric viruses to chickens induces an immune response in the animal against both ndv and iltv.
The United States Of America, As Represented By The Secretary Of Agriculture


 Multivalent vlp conjugates patent thumbnailMultivalent vlp conjugates
The invention is directed to vaccines comprising capsular polysaccharides conjugated to one or more components of virus like particles (vlp), and methods for the administration of and methods for the manufacture of vaccines of the invention. Preferably vaccines of the invention generate a therapeutically effective response in an individual in need thereof to multiple strains and/or serotypes of the same or of different infectious agents.
Inventprise, Llc


 Salmonella choleraesuis-salmonella typhimurium vaccines patent thumbnailSalmonella choleraesuis-salmonella typhimurium vaccines
The present invention relates methods of reducing fecal shedding of animals infected with salmonella by use of a vaccine or immunogenic composition of salmonella choleraesuis-typhimurium.. .
Boehringer Ingelheim Vetmedica, Inc.


 Ehrlichial invasin for immuniztion, diagnosis, and cell delivery patent thumbnailEhrlichial invasin for immuniztion, diagnosis, and cell delivery
Disclosed are vaccines containing one or more immunogenic polypeptides derived from an etpe protein from an ehrlichia sp. Or nucleic acid encoding these polypeptides.
Ohio State Innovation Foundation


 Immunogenic liposomal formulation patent thumbnailImmunogenic liposomal formulation
A liposomal composition comprising a liposome and an aminoalkansulfonic buffer is described and claimed.. .
Glaxosmithkline Biologicals, Sa


 Vaccine compositions comprising a saponin adjuvant patent thumbnailVaccine compositions comprising a saponin adjuvant
The present invention provides a human dose of an immunogenic composition comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of quillaja saponaria molina presented in the form of a liposome and a lipopolysaccharide wherein said saponin fraction and said lipopolysaccharide are both present in said human dose at a level of below 30 μg. The present invention further provides an adjuvant composition in a human dose suitable volume comprising between 1 and 30 μg of a lipopolysaccharide and between 1 and 30 μg of an immunologically active saponin fraction presented in the form of a liposome..
Glaxosmithkline Biologicals S.a.


 Immunogenic composition patent thumbnailImmunogenic composition
The present application discloses an immunogenic composition comprising at least 2 different n. Meningitidis capsular saccharides, wherein one or more is/are selected from a first group consisting of mena, menc, meny and menw which is/are conjugated through a linker to a carrier protein(s), and one or more different saccharides is/are selected from a second group consisting of mena, menc, meny and menw which is/are directly conjugated to a carrier protein(s)..
Glaxosmithkline Biologicals S.a.


Immunogenic peptides for inhibition and treatment of herpes simplex virus infection and conditions

Certain embodiments of the present invention provide immunogenic compositions that comprise one or more peptides having an amino acid sequence selected from the group consisting of nllttpkft and rmlgdvmav and methods for administering such compositions to a mammal and thereby inducing in the mammal a cd8+ t cell-dependent protective immunity against an hsv-1 infection, an hsv-2 infection, an hsv-1 condition, an hsv-2 condition, or combinations thereof.. .
The Regents Of The University Of California

Compositions, methods and uses for thermally stable human papillomavirus formulations

Embodiments of the present invention provide for novel compositions and methods for making and using a thermally stable human papilloma virus (hpv) formulation or other stabilized multimeric virus formulation. Certain embodiments concern lyophilizing hpv formulations in the presence or absence of adjuvants.
The Regents Of The University Of Colorado, A Body Corporate

Novel compositions and methods

The present invention is directed to a polypeptide which comprises: (i) an rv2386c protein sequence; (ii) a variant of an rv2386c protein sequence; of (iii) an immunogenic fragment of an rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis..
Glaxosmithkline Biologicals S.a.

Compounds and compositions as toll-like receptor 7 agonists

The invention provides a compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with toll-like receptor 7 activity.. .
Novartis Ag

Immunogenic composition for use in therapy

This application relates to immunogenic compositions comprising a staphylococcus aureus type 5 capsular saccharide conjugated to a carrier protein to form a s. Aureus type 5 capsular saccharide conjugate..
Glaxosmithkline Biologicals S.a.

Factor viii b cell epitope variants having reduced immunogenicity

Provided herein are methods and compositions for preventing or reducing an initial immune response to factor viii in patients suffering from hemophilia a and for reducing the intensity of the immune response in patients having pre-formed inhibitor antibodies against factor viii.. .
Bloodworks

Plasmodium falciparum antigens

The invention relates to antigens, associated with sterile immunity, and methods of their use, in an immunogenic formulation to confer an immune response against plasmodium falciparum. The inventive antigens were identified by their association with sterile immunity against malaria..
United States Of America As Represented By The Secretary Of The Navy

Epitopes cross-reactive between hsv-1, hsv-2 and vzv and methods for using same

The invention provides epitopes of hsv and vzv that are cross-reactive and are useful for the prevention and treatment of alphaherpesvirus infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against whole virus.
University Of Washington

Treatment of prdc in pigs

The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (pcv2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (prdc) in animals, preferably in pigs.. .
Boehringer Ingelheim Vetmedica, Inc.

West nile virus vaccine

The invention provides for immunogenic compositions against west nile virus. The immunogenic compositions, in alternate embodiments, also include other equine pathogens.
Boehringer Ingelheim Vetmedica, Inc.

Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs

The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (pcv2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a pcv2 infection.
Boehringer Ingelheim Vetmedica, Inc.

Live salmonella vaccine and methods to prevent fowl typhoid

We constructed s. Gallinarum strains deleted for the global regulatory gene fur (fig.
Arizona Board Of Regents On Behalf Of Arizona State University

Indoleamine 2,3-dioxygenase based immunotherapy

The use of ido and immunogenic peptide fragments hereof in cancer and infection treatment, diagnosis and prognosis is also provided.. .

Compositions comprising angiogenic factors and methods of use thereof

The present invention provides recombinant listeria strains comprising an angiogenic factor, recombinant polypeptides comprising an angiogenic factor operatively linked to a polypeptide comprising a pest-like sequence, recombinant nucleotide molecules encoding same, related vaccines, and immunogenic and therapeutic methods utilizing same.. .
The Trustees Of The University Of Pennsylvania

Pegylated tissue kallikrein, and preparation method therefor and uses thereof

The present invention relates to polyethylene glycol (peg) modified protein drugs, and a pegylated tissue kallikrein, a preparation method and use thereof are disclosed. The tissue kallikrein has a sequence as shown in seq id no.
Gensun Institute Of Biomedicine Co.,ltd.

Endoglin antibodies

The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both.
Tracon Pharmaceuticals, Inc.

Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors

The present invention describes combination treatment comprising a pd-1 axis binding antagonist and an agent that decreases or inhibits tigit expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.. .
Genentech, Inc.

Compounds and compositions as toll-like receptor 7 agonists

The invention provides a compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with toll-like receptor 7 activity.. .
Novartis Ag

Rna containing modified nucleosides and methods of use thereof

This invention provides rna, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of rna, oligoribonucleotide, and polyribonucleotide molecules..
The Trustees Of The University Of Pennsylvania

Novel use of multi-arm polyethylene glycol modifier and application of multi-arm polyethylene glycol modifier in l-asparaginasum modification

Methods for use of a multi-arm polyethylene glycol (peg) modifier in modification of asparaginase. The described multi-arm peg modifier enhances the subunit interaction of a multimeric protein to maintain the multimeric protein in a polymerized form, thereby improving the stability of the multimeric protein, maintaining the bioactivity of the multimeric protein, and reducing the probability of exposure of the antigen binding site after depolymerization of the subunits, so as to reduce the immunogenicity..
Gensun Institute Of Biomedicine Co.,ltd.

Antibody-mediated disruption of quorum sensing in bacteria

The invention provides an immunogenic molecular entity and related vaccines that can be used to inhibit gram-positive bacterial quorum sensing, prevent infection or development of a disease condition associated with a gram-positive bacterial infection. The invention also provides methods of inhibiting gram-positive bacterial quorum sensing, and methods of preventing infection or development of a disease condition associated with a gram-positive bacterial infection..

Compositions for antigen-specific induction of tolerance

The invention relates to an immunogenic composition far sublingual, perlingual or oral administration, comprising at least an antigen and at least an adjuvant that is a bacterium selected from a bifidobacterium and a lactic acid bacterium, and or a combination of a corticosteroid with vitamin d3 or any metabolite or analog of the latter, in a pharmaceutically acceptable carrier that is suitable tor sublingual, perlingual, or oral administration. Such compositions allow to elicit antigen-specific immune tolerance..
Stallergenes

Chimeric therapeutics, compositions, and methods for using same

Chimeric therapeutics are disclosed that include a modified viral core protein comprising at least one mutation or modification in an immunogenic epitope and a therapeutic agent. The therapeutic agent may be associated with the modified viral core protein and may be a nucleic acid, a protein, or a small molecule.
Biomed Realty, L.p.

Recombinant turkey herpesvirus vaccines and uses thereof

The present disclosure provides a recombinant viral vector comprising at least one transgene inserted into a marek's disease viral genome for treatment of diseases in poultry. Also provided are immunogenic compositions comprising such recombinant viral vectors and methods for preventing or inhibiting marek's disease in combination with at least a second disease in poultry..
The Texas A&m University System

Chlamydia antigens and uses thereof

The present invention provides novel chlamydia antigens, nucleic acids encoding the antigens, and immunogenic compositions including the antigens. The present invention further provides methods of using the antigens to elicit immune responses (e.g., t cell-mediated and/or b cell-mediated immune responses).
Genocea Biosciences, Inc.

Multi-indication mrna cancer immunotherapy

Synthetic bacterial messenger rna can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mrna obtained from dna that encodes an immunogenic bacterial protein.
Morphogenesis, Inc.

Antigens of pneumocystis murina and uses thereof

A surface protein of the murine fungal pathogen pneumocystis murina can be used to generate an immune response in a recipient animal or human that provides prophylactic protection and an anti-fungal activity in subjects already infected with a pneumocystis species. Further, the disclosure provides novel polypeptides or peptides derived from the p.
The University Of New Orleans

Liquid amnion transplant product

A transplant product made from human amniotic fluid has a supernatant from filtered and centrifuged amniotic fluid, the amniotic fluid when recovered aseptically having a clear, translucent to slightly pink or tan color. The supernatant had been taken from the amniotic fluid which had been passed through a 170 to 260 micron blood filter, then centrifuged for 5 minutes or more at 400 g and thereafter the supernatant was separated from a pellet of debris, leaving the biochemical properties intact, wherein the supernatant is cryofrozen in sized cryovials having 0.25 to 2.0 ml of the supernatant at a temperature of −65 degrees or less prior to use and the transplant products method of use.
Vivex Biomedical, Inc.

Modified forms of pseudomonas exotoxin a

Pseudomonas exotoxin a or “pe” is a 66 kd, highly potent, cytotoxic protein secreted by the bacterium pseudomonas aeruginosa. Various forms of pe have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells).
Intrexon Corporation

Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies

Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (psma) are provided. The modified anti-psma antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human.

Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors

The present invention describes combination treatment comprising a pd-1 axis binding antagonist and an agent that decreases or inhibits tigit expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.. .
Genentech, Inc.

Fibronectin binding domains with reduced immunogenicity

Fibronectin type iii (10fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism.
Bristol-myers Squibb Company

Multi-functional mucosal vaccine platform

An immunogenic fusion protein for use as a mucosal vaccine is provided, which includes: i) one or more fcyri-binding domains; ii) one or more antigens from one or more infectious disease organisms; and iii) one or more fcrn-binding domains.. .
University Of Washington

Soluble hiv-1 envelope glycoprotein trimers

The present application relates to novel hiv-1 envelope glycoproteins which may be utilized as an hiv-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention..
The Scripps Research Institute

Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a

The present invention relates to compositions comprising haemophilus influenzae protein e and pilin a. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising protein e and pila, vaccines comprising such immunogenic compositions and therapeutic uses of the same..
Glaxosmithkline Biologicals S.a.

Pcv2 orf2 protein variant and virus like particles composed thereof

Vaccination methods to control pcv2 infection with different pcv2 subtypes are disclosed. Specifically, a pcv2 subtype b (pcv2b) orf2 proteins or immunogenic compositions comprising a pcv2b orf2 protein are used in a method for the treatment or prevention of an infection with pcv2 of the same pcv2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with pcv2 of the same pcv2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with pcv2 of the same pcv2b and/or a different subtype.
Boehringer Ingelheim Vetmedica, Inc.

Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses

A fusion protein for use as an immunogen enhancer for enhancing antigen-specific t cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (apc)-binding domain or a cd91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen of a pathogen, wherein the apc-binding domain or the cd91 receptor-binding domain is located at the n-terminus of the fusion protein, and the antigen of the pathogen is located at the c-terminus of the protein transduction domain.
Thevax Genetics Vaccine Co., Ltd.

Toll-like receptor-7 and -8 modulatory 1h imidazoquinoline derived compounds

The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using such compounds. The present disclosure also provides tlr7 agonists and tlr7/tlr8 dual agonists, probes, tissue-specific molecules, adjuvants, immunogenic compositions, therapeutic compositions, and self-adjuvanting vaccines including the imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof.
The University Of Kansas

Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor

Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of raav particles.
The Trustees Of The University Of Pennsylvania

Peptide sequences and compositions

Wherein, the polypeptide is immunogenic in a vertebrate expressing a major histocompatibility complex (mhc) allele, and wherein the polypeptide is not a complete influenza virus protein.. .

Immunogenic composition of killed leptospira bacteria

The present invention pertains to a composition containing an immunogenic cell preparation of killed leptospira bacteria in an ethylenediaminetetraacetic acid solution. The invention also pertains to a vaccine to protect an animal against an infection with leptospira bacteria, wherein the vaccine comprises this composition.
Intervet Inc.

Heat inactivated poxvirus improves vaccination results

Compositions including a heat-inactivated poxvirus, such as vaccinia virus, that induces one or more interferons in a vaccine recipient. The compositions may further include one or more live vaccine vectors and non-replicating vaccine components.
Arizona Board Of Regents On Behalf Of Arizona State

Vaccine compositions

The present invention relates to the use of an excipient which is a compound of formula (i) or a physiologically acceptable salt or ester thereof: wherein: r1 represents c1-6alkyl; r2 represents hydrogen or c1-6alkyl; and r3 represents c1-6alkyl, for increasing the immunogenicity of an influenza antigen, which use comprises (a) freezing, (b) heat-treating, and/or (c) freeze-drying an aqueous composition comprising the influenza antigen and the excipient.. .
Stabilitech Ltd.

Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof

The present invention relates to new immunogenic compositions comprising conjugated streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a s.
Pfizer Inc.

Augmentation of cancer and cancer endothelial vaccine immunogenicity by histone deacetylase inhibitors

Disclosed are protocols, procedures and therapeutic compositions useful for augmentation of immunity to cancer and cancer associated endothelial cells by treatment with histone deacetylase (hdac) inhibitors capable of augmenting stimulatory and costimulatory molecules on said cancer vaccines. Additionally, the invention teaches specific concentrations of hdac inhibitors useful for stimulation of in vivo immunity to tumor and tumor endothelial cell targeting vaccines..
Batu Biologics, Inc.



Immunogenic topics:
  • Immunogenic
  • Polypeptide
  • Recombinant
  • Amino Acid
  • Amino Acid Sequence
  • Immune Response
  • Mycobacterium
  • Vaccination
  • Monoclonal
  • Monoclonal Antibody
  • Antibodies
  • Cytotoxic T Lymphocyte
  • Lymphocyte
  • Amino Acids
  • Hla Antigen


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Immunogenic for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunogenic with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.2885

    file did exist - 2582

    1 - 1 - 55